Canada, US Hold Fresh Trade Talks as August 19 Tariff Deadline Nears 
North Korea Slams Japan’s 2026 Defense White Paper 
Trump Weighs Capital Gains Tax Cuts Ahead of Midterms 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Myanmar Rejects ASEAN Special Envoy, Challenges Regional Peace Plan 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Bashar al-Assad Sentenced to Death by Syrian Court 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Darline Graham Advances to South Carolina Senate Runoff 
3 clinical-grade skincare creams you really shouldn’t buy online 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Houthi Attack on Yemen’s Mocha Port Kills Seven, Injures 30 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Ukraine Accuses Russia of Systematic Torture of POWs and Civilian Detainees 
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) is facing leadership uncertainty after acting director Jeffery Taubenberger stepped down during ongoing Ebola and hantavirus outbreak concerns. The departure was revealed Thursday during a Senate hearing on the National Institutes of Health (NIH) 2027 budget, sparking criticism from Democratic lawmakers over the agency’s preparedness for emerging infectious diseases.
Taubenberger assumed the acting director role in April 2025 after the Trump administration removed former NIAID leadership. Senator Tammy Baldwin announced his resignation at the hearing, while Senator Patty Murray also referenced the sudden exit. NIH Director Jay Bhattacharya did not deny the reports and said the agency is shifting priorities away from civilian biodefense and pandemic preparedness toward direct infectious disease response, allergy research, and immunology.
The leadership change comes as global health officials monitor an Ebola outbreak in the Democratic Republic of Congo and potential hantavirus exposure linked to a luxury cruise ship outbreak in the Atlantic Ocean. Although no confirmed U.S. cases of Andes hantavirus have been reported, 41 individuals, including 18 people quarantined in Nebraska, remain under observation.
Former NIAID director Jeanne Marrazzo criticized the current situation, warning that the institute appears disconnected from researchers and pharmaceutical companies working on Ebola treatments. Under former director Anthony Fauci, NIAID played a major role in managing both the COVID-19 pandemic and the 2014-2016 Ebola crisis in West Africa.
The latest departures add to growing concerns about instability within the NIH, where more than half of its 27 institutes are currently overseen by acting directors. NIAID, the NIH’s second-largest institute with a budget exceeding $6.5 billion, remains central to U.S. infectious disease research and public health response efforts.
